Telomir Pharmaceuticals (NASDAQ:TELO) versus Sonnet BioTherapeutics (NASDAQ:SONN) Head-To-Head Contrast

Sonnet BioTherapeutics (NASDAQ:SONN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Profitability

This table compares Sonnet BioTherapeutics and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonnet BioTherapeutics	-11,187.19%	-398.45%	-142.16%
Telomir Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

9.4% of Sonnet BioTherapeutics shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sonnet BioTherapeutics and Telomir Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonnet BioTherapeutics	0	0	2	0	3.00
Telomir Pharmaceuticals	0	0	0	0	N/A

Sonnet BioTherapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 3,352.24%. Given Sonnet BioTherapeutics’ higher probable upside, research analysts plainly believe Sonnet BioTherapeutics is more favorable than Telomir Pharmaceuticals.

Earnings and Valuation

This table compares Sonnet BioTherapeutics and Telomir Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonnet BioTherapeutics	$55,881.00	48.39	-$18.83 million	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$13.07 million	N/A	N/A

Telomir Pharmaceuticals has lower revenue, but higher earnings than Sonnet BioTherapeutics.

Summary

Sonnet BioTherapeutics beats Telomir Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.